Stockscreener 앱 받기
2.37
7.73%
0.17
시간 외 거래:
2.38
0.010
+0.42%
전일 마감가:
$2.20
열려 있는:
$2.18
하루 거래량:
1.88M
Relative Volume:
1.50
시가총액:
$167.25M
수익:
-
순이익/손실:
$-117.50M
주가수익비율:
-0.9258
EPS:
-2.56
순현금흐름:
$-114.31M
1주 성능:
+1.28%
1개월 성능:
-5.20%
6개월 성능:
-55.24%
1년 성능:
-35.42%
1일 변동 폭
$2.15
$2.405
1주일 범위
$2.08
$2.50
52주 변동 폭
$2.08
$16.24
엔카르타 Stock (NKTX) Company Profile
명칭
Nkarta Inc
전화
(925) 407-1049
주소
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
NKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.37 | 167.25M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
엔카르타 Stock (NKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-08-14 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-07-28 | 개시 | Needham | Buy |
| 2022-07-18 | 개시 | SVB Leerink | Outperform |
| 2022-03-11 | 개시 | Raymond James | Outperform |
| 2022-03-08 | 개시 | H.C. Wainwright | Buy |
| 2022-01-06 | 개시 | William Blair | Outperform |
| 2021-11-18 | 개시 | SMBC Nikko | Outperform |
| 2021-07-16 | 개시 | Oppenheimer | Outperform |
| 2020-08-04 | 개시 | Cowen | Outperform |
| 2020-08-04 | 개시 | Evercore ISI | Outperform |
| 2020-08-04 | 개시 | Mizuho | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
엔카르타 주식(NKTX)의 최신 뉴스
Fmr LLC Has $602,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase By Investing.com - Investing.com Australia
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase - Investing.com India
Citadel Advisors LLC's Strategic Acquisition of Nkarta Inc Shares - GuruFocus.com
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment By Investing.com - Investing.com South Africa
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment - Investing.com UK
Major Improvements In Nkarta Inc (NKTX) Stock Need To Be Considered - Stocks Register
Nkarta’s Ntrust-2 trial of NKX019 in myasthenia gravis begins enrollment - TipRanks
Nkarta Announces IND Clearance of Investigator-Sponsored - GlobeNewswire
Nkarta Expands NKX019 Cell Therapy Trial to 4 New Autoimmune Diseases, Breakthrough Treatment Protocol Unveiled - StockTitan
Wasatch Advisors LP Has $8.29 Million Stake in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Sees Large Drop in Short Interest - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Brokerages - MarketBeat
Nkarta to Participate in an Upcoming Investor Conference - GlobeNewswire
Nkarta to Present NK Cell Therapy Advances at Evercore HealthCONx Conference | NKTX Stock News - StockTitan
Nkarta price target lowered to $16 from $20 at Mizuho - Yahoo Finance
Mizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $16.00 - MarketBeat
NKTX stock touches 52-week low at $2.44 amid market fluctuations - Investing.com
COMMODORE CAPITAL LP Acquires Shares in Nkarta Inc - GuruFocus.com
Despite Hitting US$2.91, Nkarta Insiders Still Sold Too Soon - Simply Wall St
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Nkarta to Present at Stifel Healthcare Conference: NK Cell Therapy Updates Expected | NKTX Stock News - StockTitan
Nkarta (NASDAQ:NKTX) Price Target Cut to $18.00 by Analysts at HC Wainwright - MarketBeat
Nkarta (NASDAQ:NKTX) Given New $11.00 Price Target at Needham & Company LLC - MarketBeat
Nkarta, Inc. Reports Q3 2024 Financial Results - TipRanks
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta, Inc. (NASDAQ:NKTX) Receives $17.50 Average PT from Brokerages - Defense World
Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $17.50 - MarketBeat
Nkarta (NKTX) Stock: Looking For Upside - Seeking Alpha
Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade) - Seeking Alpha
SG Americas Securities LLC Purchases New Shares in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Bleakley Financial Group LLC Has $69,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth - Yahoo Finance
GAMMA Investing LLC Increases Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Are Nkarta Inc (NKTX) shares a good deal now? - US Post News
Daily Market Movement: Nkarta Inc (NKTX) Sees a 1.29 Increase, Closing at 3.94 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Dimensional Fund Advisors LP - Defense World
AQR Capital Management LLC Invests $938,000 in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta Inc (NKTX) Stock: A Year of Market Fluctuations - The InvestChronicle
Nkarta (NASDAQ:NKTX) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
Nkarta (NASDAQ:NKTX) Upgraded to "Strong-Buy" by RODMAN&RENSHAW - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Nkarta (NASDAQ:NKTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Raymond James upgrades Nkarta Inc (NKTX) stock to a Strong buy - Knox Daily
Nkarta upgraded at Raymond James on valuation - MSN
엔카르타 (NKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엔카르타 주식 (NKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Trager James | Chief Scientific Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
150,959 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '24 |
Sale |
5.60 |
1,770 |
9,912 |
240,737 |
| Shook David | Chief Medical Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
116,524 |
| Hager Alicia J. | Chief Legal Officer |
Jun 18 '24 |
Sale |
5.60 |
727 |
4,071 |
107,215 |
| Brandenberger Ralph | Chief Technical Officer |
Jun 18 '24 |
Sale |
5.60 |
229 |
1,282 |
79,743 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '24 |
Buy |
10.00 |
3,000,000 |
30,000,000 |
10,050,818 |
| George Simeon | Director |
Mar 27 '24 |
Buy |
10.00 |
2,000,000 |
20,000,000 |
1,548,341 |
| Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Option Exercise |
3.89 |
6,763 |
26,308 |
88,339 |
| Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Sale |
12.51 |
8,367 |
104,671 |
79,972 |
| Trager James | Chief Scientific Officer |
Feb 12 '24 |
Sale |
12.00 |
4,143 |
49,716 |
149,415 |
2.88%
2.65%
자본화:
|
볼륨(24시간):